CLAUDIO-01 is the first-in-human trial of SOT102, a CLDN18.2 (Claudin 18.2) targeting antibody-drug conjugate (ADC)The trial will enroll up to 109 patients with gastric and pancreatic cancer PRAGUE
CLAUDIO-01 is the first-in-human trial of SOT102, a 2 (Claudin 18.2) targeting antibody-drug conjugate (ADC) The trial will enroll up to 109 patients with gastric and pancreatic cancerPRAGUE, Czech Republic, April 26, 2022 / B3C newswire / SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group.
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has dosed the first patient in its Phase 1/2 CLAUDIO-01 trial of SOT102 in patients with gastric and pancreatic cancer. SOT102 is the lead program of SOTIO’s growing ADC pipeline built on multiple platforms. “Antibody ..
SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer b3cnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from b3cnewswire.com Daily Mail and Mail on Sunday newspapers.
COVID-19 Collection thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.